Photo: Arantxa García (Director of Cardiovascular, Renal and Metabolic Diseases Medicine), Diana Riba (Medical Advisor), Antoni Bayés (IGTP), Oriol Iborra (IGTP), Martin Plotquin (Director of Medicine and R&D), Victor Martín (Medical Transformation Officer), Carolina Gálvez and Carles Esquerré (IGTP).

• The agreement includes the development of a new line of research to assess the potential of new molecules in the field of cardio-renal-metabolic diseases.
• Boehringer Ingelheim's collaboration with IGTP began in 2020 with the aim of improving knowledge about cardio-renal-metabolic entities and their interconnection.
• Boehringer Ingelheim is currently running 107 basic, preclinical and clinical research projects in collaboration with more than 70 leading centres across Spain.

The biopharmaceutical company Boehringer Ingelheim has signed a new collaboration agreement with the Germans Trias i Pujol Research Institute (IGTP), launching a new research project focused on evaluating the potential benefits of a new molecule targeting the cardio-renal-metabolic axis.

This alliance is part of a strategic collaboration established in 2020 between Boehringer Ingelheim and the Germans Trias Heart Institute (iCor), affiliated with IGTP, to enhance current knowledge of cardiovascular, renal and metabolic (CRM) diseases. The partnership also explores the interconnection between these conditions with the aim of improving disease understanding and enabling the development of innovative prevention and treatment strategies. Over the past few years, the teams have worked on four projects investigating the effects of empagliflozin in heart failure and myocardial infarction, while also exploring new potential therapeutic targets. The most recent of these studies, published in the Journal of the American Heart Association, evaluated how empagliflozin may improve heart function in the context of myocardial infarction.

"Innovation is part of our DNA, and this alliance clearly demonstrates our commitment to driving science as a force for transformation. Collaborating on preclinical research projects with IGTP reinforces our belief that institutional partnerships can generate a real impact on people's lives", states Martín Plotquin, director of Medicine and R&D at Boehringer Ingelheim Spain. "This new partnership aligns with our global strategy to promote innovation through alliances with leading centres such as IGTP", he adds.

Dr Antoni Bayés-Genís, director of iCor, points out that "this collaboration strengthens our commitment to translational research in the cardio-renal-metabolic field. Our work with Boehringer Ingelheim has advanced the understanding of key pathophysiological mechanisms and allowed us to explore new therapeutic strategies with clear potential clinical impact. This new preclinical line opens the door to continued generation of scientific evidence that could benefit patients in the near future".

This new agreement is part of Boehringer Ingelheim's broader strategy to continue driving innovation as a lever for transformation in the healthcare system. In fact, in 2024 the company increased its R&D investment by 53%, reaching €105 million. Of this total, €20.4 million was allocated to clinical research in Spain. Boehringer Ingelheim is currently running 107 basic, preclinical and clinical research projects in partnership with over 70 leading centres throughout the country.